0.23
8.73%
-0.022
After Hours:
.2279
-0.0021
-0.91%
InMed Pharmaceuticals Inc stock is currently priced at $0.23, with a 24-hour trading volume of 476.02K.
It has seen a -8.73% decreased in the last 24 hours and a -33.35% declined in the past month.
The chart indicates a potential bearish trend, as the stock is below the $0.2558 pivot point. If it approaches the $0.2307 support level, significant changes may occur.
Previous Close:
$0.252
Open:
$0.245
24h Volume:
476.02K
Market Cap:
$1.39M
Revenue:
$5.49M
Net Income/Loss:
$-6.35M
P/E Ratio:
-0.0435
EPS:
-5.29
Net Cash Flow:
$-6.51M
1W Performance:
-20.70%
1M Performance:
-33.35%
6M Performance:
-66.10%
1Y Performance:
-80.83%
InMed Pharmaceuticals Inc Stock (INM) Company Profile
Name
InMed Pharmaceuticals Inc
Sector
Industry
Phone
-
Address
815 West Hastings Street, Suite 310, Vancouver
InMed Pharmaceuticals Inc Stock (INM) Latest News
InMed Pharmaceuticals And 2 Other Penny Stocks Insiders Are Buying
Benzinga
Charles & Colvard And 3 Other Stocks Under $2 Insiders Are Buying
Benzinga
Why BlackBerry Shares Are Trading Lower By Over 5%; Here Are 20 Stocks Moving Premarket
Benzinga
Investment Chief At $48B Global X Forecasts AI Stock Dominance In 2024: Unveils Top Investment Opportunities
Benzinga
InMed Pharmaceuticals Inc Stock (INM) Financials Data
InMed Pharmaceuticals Inc (INM) Revenue 2024
INM reported a revenue (TTM) of $5.49 million for the quarter ending December 31, 2023, a +239.78% rise year-over-year.
InMed Pharmaceuticals Inc (INM) Net Income 2024
INM net income (TTM) was -$6.35 million for the quarter ending December 31, 2023, a +62.54% increase year-over-year.
InMed Pharmaceuticals Inc (INM) Cash Flow 2024
INM recorded a free cash flow (TTM) of -$6.51 million for the quarter ending December 31, 2023, a +54.71% increase year-over-year.
InMed Pharmaceuticals Inc (INM) Earnings per Share 2024
INM earnings per share (TTM) was -$1.27 for the quarter ending December 31, 2023, a +94.53% growth year-over-year.
About InMed Pharmaceuticals Inc
InMed Pharmaceuticals Inc., a clinical stage pharmaceutical company, develops a pipeline of prescription-based products. The company operates through two segments, the InMed and the BayMedica. The InMed segment researches and develops cannabinoid-based pharmaceuticals products. The BayMedica segment develops proprietary manufacturing technologies to produce and sell rare cannabinoids for the health and wellness industry. The company's prescription-based products include rare cannabinoids and novel cannabinoid analogs for the treatment of diseases with high unmet medical needs. Its lead product is INM-755, a cannabinol topical skin cream, which is in Phase 2 clinical trial for the treatment of epidermolysis bullosa. The company is also developing INM-088, which is in preclinical studies for the treatment of glaucoma; INM-405 for the treatment of pain; and cannabinoid-based treatments for various diseases, including dermatology and ocular diseases. In addition, it offers IntegraSyn, an integrated biosynthesis-based manufacturing approach, for pharmaceutical-grade cannabinoids; and cannabichromene, cannabicitran, cannabidivarin, and tetrahydrocannabivarin. The company was formerly known as Cannabis Technologies Inc. and changed its name to InMed Pharmaceuticals Inc. in October 2014. InMed Pharmaceuticals Inc. was incorporated in 1981 and is headquartered in Vancouver, Canada.
Cap:
|
Volume (24h):